Original news and analysis on international IP policy
By Dugie Standeford for Intellectual Property Watch In a flurry of intellectual property-related activity, the European Commission this week ordered copyright collecting societies to loosen their stranglehold on cross-border music licensing, proposed extending the term of copyright protection to 95…
By Catherine Saez Standards and intellectual property rights appear to be worlds apart and to respond to opposite purposes, according to a recent panel of legal and policy experts. While standards are established to ensure compatibility in technology to the…
By Wagdy Sawahel for Intellectual Property Watch CAIRO – African countries recently approved a plan to set up a parliamentary knowledge network to enhance legislative and institutional capacity for creating science and technology-based legislation including intellectual property rights. But the…
By Liza Porteus Viana for Intellectual Property Watch
When Biotechnology Industry Organization CEO Jim Greenwood meets with members of the United States Congress to talk to them about follow-on biologics, he brings a graphic model of an aspirin and a DVD showing the complex molecules of a biologic drug. He uses these visuals to help explain the differences between traditional chemical drugs and newer, cutting-edge biological ones being used in many breakthrough therapies for cancer, multiple sclerosis, HIV/AIDS, and other diseases.
The differences between traditional chemical drugs and biological ones is the crux of the debate going on in the United States as Congress and the Food and Drug Administration (FDA) try to create a regulatory pathway that gives consumers greater access to cheaper, generic biological drugs, but still spurs innovation and protects innovator patent claims.
"When the legislation was introduced at the beginning of this Congress, most pundits expected that we'd oppose it," said Greenwood, a former House representative from Pennsylvania, told Intellectual Property Watch. "But that was a mistake the pharmaceutical industry made in the '80s - trying to resist the notion you could safely make generics …our view at BIO is that we need to follow the science, and science says you can make follow-on biologics that can be safe and can save the consumer money and therefore we support it."
By Monika Ermert for Intellectual Property Watch Despite earlier statements by European negotiators that the planned Anti-Counterfeiting Trade Agreement (ACTA) would need time for fine-tuning, nations seem to accept a fast track movement now. ACTA has been mentioned as an…
By Kaitlin Mara A confidential draft text circulated recently among some World Trade Organization members reveals an attempt to consolidate separate proposals aimed at the protection of product names with location-related associations and characteristics (called geographical indications) and at the…
A confidential text, dated 30 June and available here, and circulated recently among some World Trade Organization members reveals an attempt to consolidate separate proposals on the protection of geographical indications, biodiversity and traditional knowledge.
By Wagdy Sawahel for Intellectual Property Watch Seventeen African ministers of arts and culture have officially launched the newly formed Southern and Eastern Africa Copyright Network (Seaconet) in a bid to strengthen regional collaboration and cooperation in the field of…
By Kaitlin Mara
Intellectual property is a useful leveraging tool for developing countries eager to see the creation of a global access and benefit-sharing regime on genetic resource use, said a recent panel on biodiversity protections in international law.
"Benefit-sharing was viewed as an integral part of the main bargain between developed and developing countries" when the Convention on Biological Diversity (CBD) was first formed, said Timothy Hodges, a Canadian official who co-chairs an access and benefit-sharing working group under the CBD.
By William New The World Intellectual Property Organization’s newest and potentially highest impact committee – aimed at ensuring all of the organisation’s activities are sufficiently development-friendly to fit its wide-ranging membership – completed its first year with some concrete progress…